---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-194655"
form_type: "8-K"
ticker: "AMLX"
cik: "0001658551"
company_name: "Amylyx Pharmaceuticals, Inc."
filed_at: "2023-07-26T23:59:59+00:00"
generated_at: "2026-06-13T02:22:30.922716+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "low"
source: SEC EDGAR
---

# Amylyx announces conference call on AMX0035 Phase 3 PSP trial; no new data

## Summary
- Hosted investor call on July 26, 2023 to discuss PSP and Orion Phase 3 trial of AMX0035.
- No clinical results or data disclosed; only trial design and scientific rationale overview.
- Presenters included co-CEOs, clinical development head, and external investigator Prof. Höglinger.
- Attached slides outline rationale and design, not outcomes or milestones.

## SEC filing metadata
- accession: 0001193125-23-194655
- form_type: 8-K
- ticker: AMLX
- cik: 0001658551
- company_name: Amylyx Pharmaceuticals, Inc.
- filed_at: 2023-07-26T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: low
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658551/000119312523194655/0001193125-23-194655-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658551/000119312523194655/d498667d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-194655
- JSON: https://secwatch.observer/filing/0001193125-23-194655.json
- Plain text: https://secwatch.observer/filing/0001193125-23-194655.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.